Key result
Antiplatelet therapy discontinuation occurred in 14.4% of patients during the first year after drug-eluting stent implantation, with renal impairment (OR 2.81) as a significant predictor.
Why the study?
What are the incidence and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation?
Population
1,622 patients receiving at least 1 drug-eluting stent between January and April 2008 across 29 hospitals.
Design
Cohort
Follow-up
12 months
Authors
Loading...
Renal impairment signals need for closer adherence monitoring post-stenting; extends predictor data but leaves causal outcome impact open.
Cohort (n=1,622)
Yes
What are the incidence and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation?
Antiplatelet therapy discontinuation in the first year after drug-eluting stent implantation occurs in 14.4% of patients and is driven by bleeding, medical decisions, and patient-initiated factors.
Ferreira‐González et al. (2010) conducted a cohort in Drug-eluting stent implantation (n=1,622). Clinical and demographic risk factors was evaluated on Antiplatelet therapy discontinuation (ATD). Antiplatelet therapy discontinuation occurred in 14.4% of patients during the first year after drug-eluting stent implantation, with renal impairment (OR 2.81) as a significant predictor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: